Insulin Glulisine
- Generic Name
- Insulin Glulisine
- Brand Names
- Apidra
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 207748-29-6
- Unique Ingredient Identifier
- 7XIY785AZD
- Background
Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insul...
- Indication
用于治疗成人糖尿病。
- Associated Conditions
- Diabetes Mellitus, Type 1 Diabetes Mellitus, Hyperglycemia during critical illness
- Associated Therapies
- -
baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2010-09-17
- Last Posted Date
- 2014-03-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 206
- Registration Number
- NCT01204593
- Locations
- 🇩🇿
Investigational Site Number 01202, Algiers, Algeria
🇦🇷Investigational Site Number 03201, Caba, Argentina
🇿🇦Investigational Site Number 12468, Benoni, South Africa
Intensive Insulin Glulisine Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering Drugs
- Conditions
- Interventions
- First Posted Date
- 2010-09-16
- Last Posted Date
- 2012-08-30
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 207
- Registration Number
- NCT01203111
- Locations
- 🇻🇪
Administrative office, Caracas, Venezuela
Apidra Children & Adolescents Study
- Conditions
- Interventions
- First Posted Date
- 2010-09-15
- Last Posted Date
- 2012-12-18
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 100
- Registration Number
- NCT01202474
- Locations
- 🇷🇺
Administrative office, Moscow, Russian Federation
Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2010-09-02
- Last Posted Date
- 2014-08-20
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 132
- Registration Number
- NCT01194258
- Locations
- 🇺🇸
Mercury Street Medical, Butte, Montana, United States
🇺🇸UT Southwestern Medical Center at Dallas, Dallas, Texas, United States
🇺🇸John Muir Physician Network Clinical Research Center, Concord, California, United States
Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2010-09-02
- Last Posted Date
- 2019-02-26
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 135
- Registration Number
- NCT01194245
- Locations
- 🇺🇸
Mercury Street Medical, Butte, Montana, United States
🇺🇸Mid-America Diabetes Associates, Wichita, Kansas, United States
🇺🇸Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States
Pharmacodynamic and Pharmacokinetic Effects of Insulin Glulisine in Obese Subjects With Type 2 Diabetes After a Standard Meal in Comparison to Insulin Aspart
- Conditions
- Interventions
- First Posted Date
- 2010-07-09
- Last Posted Date
- 2010-07-16
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 37
- Registration Number
- NCT01159353
- Locations
- 🇫🇷
Sanofi-Aventis Administrative Office, Paris, France
Diabetes in the Elderly: Prospective Study
- Conditions
- Interventions
- First Posted Date
- 2010-05-26
- Last Posted Date
- 2014-12-31
- Lead Sponsor
- Guillermo Umpierrez
- Target Recruit Count
- 150
- Registration Number
- NCT01131052
- Locations
- 🇺🇸
Guillermo Umpierrez, Atlanta, Georgia, United States
Evaluation of the Safety and Efficacy of Insulin Glargine + Glulisine or Insulin Regular + NPH Insulin (Isophane Insulin) Use in Type 2 Diabetes Mellitus Patients With Moderate Renal Failure.
- Conditions
- Interventions
- First Posted Date
- 2010-05-13
- Last Posted Date
- 2013-11-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 72
- Registration Number
- NCT01122979
- Locations
- 🇧🇷
Investigational Site Number 076-013, São Paulo, Brazil
🇧🇷Investigational Site Number 076-007, Curitiba, Brazil
🇧🇷Investigational Site Number 076-005, São Paulo, Brazil
Insulins Glargine and gluLisine strAtegy Versus Premixed Insulin strAteGy: a cOmparative Study
- Conditions
- Interventions
- First Posted Date
- 2010-05-12
- Last Posted Date
- 2013-04-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 934
- Registration Number
- NCT01121835
- Locations
- 🇨🇴
Investigational Site Number 170003, Bucaramanga, Colombia
🇨🇴Investigational Site Number 170004, Pereira, Colombia
🇨🇳Investigational Site Number 156012, Haikou, China
Insulin Glargine for Diabetes Metabolism(DM)Type II Patients Under Enteral Nutrition
- Conditions
- Interventions
- First Posted Date
- 2010-03-05
- Last Posted Date
- 2012-03-27
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 15
- Registration Number
- NCT01081938
- Locations
- 🇧🇷
Sanofi-Aventis Investigational Site Number 076-007, Belo Horizonte, Brazil
🇧🇷Sanofi-Aventis Investigational Site Number 076-004, Porto Alegre, Brazil
🇧🇷Sanofi-Aventis Investigational Site Number 076-006, São José do Rio Preto, Brazil
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.